New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
NCT ID NCT07689539
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to see which works better at slowing cancer growth and extending life. About 360 adults aged 18 to 75 with good organ function and measurable tumors are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DN022150
- What this could lead to
- If successful, this could provide a new targeted treatment option for people with a specific genetic form of pancreatic cancer that has not responded to prior therapy.
- What could go wrong
- This is an early-stage drug in a phase 3 trial; it may not improve survival or could have side effects. The mutation-specific approach limits applicability to only a subset of patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Ancient acupressure meets modern medicine: can ear stimulation replace standard Anti-Nausea drugs?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New oral drug targets Cancer's growth engine in advanced tumours
- New imaging compound targets Hard-to-Spot cancers